Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes

Blood

Volumn 113, Issue 8, 2009, Pages 1768-1777

  Tiedt, Ralph ^a   Coers, Jörn ^a,b,c   Ziegler, Sandra ^d   Wiestner, Adrian ^d   Hao Shen, Hui ^a   Bornmann, Caroline ^d   Schenkel, Johannes ^b,e   Karakhanova, Svetlana ^b   De Sauvage, Frederic J ^f   Jackson, Carl W ^g   Skoda, Radek C ^a,b,d  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF BASEL   (Switzerland)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f GENENTECH INC   (United States)

^g ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; MPL PROTEIN; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; FEEDBACK SYSTEM; GENE DELETION; GENE EXPRESSION; MEGAKARYOCYTE; MOLECULAR WEIGHT; MOUSE; MYELOPROLIFERATIVE DISORDER; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; STEADY STATE; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS; THROMBOCYTOSIS; TRANSGENE; TRANSGENIC MOUSE;

EID: 61849152839     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-03-146084     Document Type: Article

References (62)

1. Kaushansky K. Thrombopoietin. N Engl J Med. 1998;339:746-754.
2. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest. 2005;115: 3339-3347.
3. Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl-deficient mice. Science. 1994;265:1445-1447.
4. de Sauvage FJ, Carver-Moore K, Luoh SM, et al. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med. 1996;183:651-656.
5. Fielder PJ, Gurney AL, Stefanich E, et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood. 1996;87:2154-2161.
6. Stoffel R, Wiestner A, Skoda RC. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood. 1996;87:567-573.
7. Alexander WS, Roberts AW, Nicola NA, Li R, Metcalf D. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the throm-bopoietic receptor c-Mpl. Blood. 1996;87:2162-2170.
8. Solar GP, Kerr WG, Zeigler FC, et al. Role of c-mpl in early hematopoiesis. Blood. 1998;92:4-10.
9. Ihara K, Ishii E, Eguchi M, et al. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci U SA. 1999;96:3132-3136.
10. van den Oudenrijn S, Bruin M, Folman CC, et al. Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic throm-bocytopenia. Br J Haematol. 2000;110:441-448.
11. Ballmaier M, Germeshausen M, Schulze H, et al. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood. 2001; 97:139-146.
12. Souyri M, Vigon I, Penciolelli JF, Heard JM, Tambourin P, Wendling F. A putative truncated cytokine receptor gene transduced by the myelo-proliferative leukemia virus immortalizes hemato-poietic progenitors. Cell. 1990;63:1137-1147.
13. Ding J, Komatsu H, Wakita A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for throm-bopoietin. Blood. 2004;103:4198-4200.
14. Teofili L, Giona F, Martini M, et al. Markers of my-eloproliferative diseases in childhood polycythe-mia vera and essential thrombocythemia. J Clin Oncol. 2007;25:1048-1053.
15. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofi-brosis with myeloid metaplasia. PLoS Med. 2006; 3:e270.
16. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006; 108:3472-3476.
17. Ziegler S, Burki K, Skoda RC. A 2-kb c-mpl promoter fragment is sufficient to direct expression to the megakaryocytic lineage and sites of embryonic hematopoiesis in transgenic mice. Blood. 2002;100:1072-1074.
18. Nakamura Y, Takano H, Osawa M, et al. Impaired erythropoiesis in transgenic mice overexpressing a truncated erythropoietin receptor. Exp Hematol. 1998;26:1105-1110.
19. Wagner K, Kafert-Kasting S, Heil G, Ganser A, Eder M. Inhibition of granulocyte-macrophage colony-stimulating factor receptor function by a splice variant of the common beta-receptor sub-unit. Blood. 2001;98:2689-2696.
20. Mitsui T, Watanabe S, Taniguchi Y, et al. Impaired neutrophil maturation in truncated murine G-CSF receptor-transgenic mice. Blood. 2003;101:2990-2995.
21. Heaney ML, Golde DW. Soluble cytokine receptors. Blood. 1996;87:847-857.
22. Coers J, Ranft C, Skoda RC.Atruncated isoform of c-Mpl with an essential C-terminal peptide targets the full-length receptor for degradation. J Biol Chem. 2004;279:36397-36404.
23. Skoda RC, Seldin DC, Chiang MK, Peichel CL, Vogt TF, Leder P. Murine c-mpl: a member of the hematopoietic growth factor receptor superfamily that transduces a proliferative signal. EMBO J. 1993;12:2645-2653.
24. Vigon I, Florindo C, Fichelson S, et al. Characterization of the murine Mpl proto-oncogene, a member of the hematopoietic cytokine receptor family: molecular cloning, chromosomal location and evidence for a function in cell growth. Onco-gene. 1993;8:2607-2615.
25. Arnold JT, Daw NC, Stenberg PE, Jayawardene D, Srivastava DK, Jackson CW. A single injection of pegylated murine megakaryocyte growth and development factor (MGDF) into mice is sufficient to produce a profound stimulation of megakaryo-cyte frequency, size, and ploidization. Blood. 1997;89:823-833.
26. Akimoto Y, Ishiyama T, Sano M, et al. [Essential thrombocythemia that transformed to myelofibro-sis after three years]. Rinsho Ketsueki. 1992;33: 520-524.
27. Jackson CW. Cholinesterase as a possible marker for early cells of the megakaryocytic series. Blood. 1973;42:413-421.
28. Long MW, Williams N. Immature megakaryocytes in the mouse: morphology and quantitation by acetylcholinesterase staining. Blood. 1981;58: 1032-1039.
29. Burstein SA, Friese P, Downs T, Mei RL. Characteristics of a novel rat anti-mouse platelet monoclonal antibody: application to studies of megakaryocytes. Exp Hematol. 1992;20:1170-1177.
30. Pillai MM, Venkataraman GM, Kosak S, Torok-Storb B. Integration site analysis in transgenic mice by thermal asymmetric interlaced (TAIL)-PCR: segregating multiple-integrant founder lines and determining zygosity. Transgenic Res. 2008; 17:749-754.
31. Stoffel R, Ziegler S, Ghilardi N, Ledermann B, de Sauvage FJ, Skoda RC. Permissive role of thrombopoietin and granulocyte colony-stimulating factor receptors in hematopoietic cell fate decisions in vivo. Proc Natl Acad Sci U S A. 1999; 96:698-702.
32. Zhang JL, Stenberg PE, Baker G, Levin J. Immu-nocytochemical identification of murine and human megakaryocyte colonies in soft-agar cultures. Histochem J. 1994;26:170-178.
33. Kimura S, Roberts AW, Metcalf D,Alexander WS. Hematopoietic stem cell deficiencies in mice lacking c-mpl, the receptor for thrombopoietin. Proc Natl Acad Sci U S A. 1998;95:1195-1200.
34. White JG. The dense bodies of human platelets: inherent electron opacity of the serotonin storage particles. Blood. 1969;33:598-606.
35. White JG. Use of the electron microscope for diagnosis of platelet disorders. Semin Thromb He-most. 1998;24:163-168.
36. Skoda RC, Seldin DC, Chiang MK, Peichel CL, Vogt TF, Leder P. Murine c-mpl: a member of the hematopoietic growth factor receptor superfamily that transduces a proliferative signal. EMBO J. 1993;12:2645-2653.
37. Luoh SM, Stefanich E, Solar G, et al. Role of the distal half of the c-Mpl intracellular domain in control of platelet production by thrombopoietin in vivo. Mol Cell Biol. 2000;20:507-515.
38. Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, et al. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell. 1995;81:695-704.
39. Shivdasani RA, Fielder P, Keller GA, Orkin SH, De Sauvage FJ. Regulation of the serum concentration of thrombopoietin in thrombocytopenic NF-E2 knockout mice. Blood. 1997;90:1821-1827.
40. Pan D, Schomber T, Kalberer CP, et al. Normal erythropoiesis but severe polyposis and bleeding anemia in Smad4 deficient mice. Blood. 2007; 110:3049-3055.
41. Vigon I, Mornon JP, Cocault L, et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci U S A. 1992;89:5640-5644.
42. Li J, Sabath DF, Kuter DJ. Cloning and functional characterization of a novel c-mpl variant expressed in human CD34 cells and platelets. Cyto-kine. 2000;12:835-844.
43. Filippi MD, Porteu F, Le Pesteur F, et al. Embryonic stem cell differentiation to hematopoietic cells: a model to study the function of various regions of the intracytoplasmic domain of cytokine receptors in vitro. Exp Hematol. 2000;28:1363-1372.
44. Emmons RVB, Reid DM, Cohen RL, et al. Human thrombopoietin levels are high when thrombocy-topenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood. 1996;87:4068-4071.
45. Choi ES, Hokom MM, Chen JL, et al. The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis. Br J Haema-tol. 1996;95:227-233.
46. Mignotte V, Deveaux S, Filipe A. Transcriptional regulation in megakaryocytes: the thrombopoietin receptor gene as a model. Stem Cells. 1996;14: 232-239.
47. Garrick D, Fiering S, Martin DI, Whitelaw E. Repeat-induced gene silencing in mammals. Nat Genet. 1998;18:56-59.
48. Horikawa Y, Matsumura I, Hashimoto K, et al. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood. 1997;90:4031-4038.
49. Moliterno AR, Hankins WD, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med. 1998;338:572-580.
50. Harrison CN, Gale RE, Pezella F, Mire-Sluis A, MacHin SJ, Linch DC. Platelet c-mpl expression is dysregulated in patients with essential throm-bocythaemia but this is not of diagnostic value Br J Haematol. 1999;107:139-147.
51. Kralovics R, Buser AS, Teo SS, et al. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood. 2003; 102:1869-1871.
52. Antonioli E, Guglielmelli P, Pancrazzi A, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia. 2005; 19:1847-1849.
53. MoliternoAR, Spivak JL. Posttranslational processing of the thrombopoietin receptor is impaired in polycythemia vera Blood. 1999;94: 2555-2561.
54. Tefferi A, Yoon SY, Li CY. Immunohistochemical staining for megakaryocyte c-mpl may complement morphologic distinction between polycythemia vera and secondary erythrocytosis. Blood. 2000;96:771-772.
55. MoliternoAR, Williams DM, Rogers O, Spivak JL. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood. 2006; 108:3913-3915.
56. Li J, Xia Y, Kuter DJ. The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocyth-aemia. BrJ Haematol. 2000;111:943-953.
57. MoliternoAR, Williams DM, Gutierrez-Alamillo LI, Salvatori R, Ingersoll RG, Spivak JL. Mpl Baltimore: athrombopoietin receptor polymorphism associated with thrombocytosis. Proc Natl Acad Sci USA. 2004;101:11444-11447.
58. Standen G, Clench T. Rapid detection of MPL Baltimore using LightCycler technology and melting curve analysis. BrJ Haematol. 2008;140:714-716.
59. KitamuraT, Onishi M, YahataT, Kanakura Y Asano S. Activating mutations of the transmembrane domain of MPL in vitro and in vivo: incorrect sequence of MPL-K, an alternative spliced form of MPL [letter]. Blood. 1998;92:2596-2597.
60. Ding J, Komatsu H, WakitaA, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of thec-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103:4198-4200.
61. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008;112:141-149.
62. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood. 2008;112:844-847.